Tilray Brands, Inc. (TLRY) · Oct 8, 2026 · Earnings
In line — Q1 adjusted EBITDA $9.2M, down 10% year over year; FY27 guide reaffirmed at $68M–$75M
Tilray earnings show 23% revenue growth and wider gross margins, but adjusted EBITDA declines, free-cash-flow losses deepen, and cannabis revenue falls.
Tilray is in the middle of a strategic shift from a cannabis-led company into a diversified global consumer-products platform, using beverage brands such as BrewDog, international medical cannabis, and pharmaceutical distribution to reduce dependence on Canadian cannabis. Its latest annual filing describes BrewDog as the move that expanded the beverage business from North America into a global platform.
The diversification is working on revenue, but mostly through beverage acquisition rather than broad-based organic acceleration. First-quarter revenue rose 23% to $257.1 million and gross profit rose 35% to $77.5 million, with total gross margin expanding to 30% from 27% (Financial Highlights). Beverage revenue jumped 82% to $101.5 million, explicitly reflecting the BrewDog acquisition, while distribution grew 14%; cannabis revenue fell 13% to $56.1 million and wellness was essentially flat (Net Revenue by Operating Segment).
| Metric | Q1 FY2027 | Q1 FY2026 | Change |
|---|---|---|---|
| Net revenue | $257.1M | $209.5M | +23% (Financial Highlights) |
| Gross profit | $77.5M | $57.5M | +35% (Financial Highlights) |
| Gross margin | 30% | 27% | +300 bps (Gross Margin table) |
| Adjusted EBITDA | $9.2M | $10.2M | -10% (Adjusted EBITDA table) |
| Operating cash flow | $(16.5)M | $(1.3)M | Worse by $15.2M (Cash Flow statement) |
| Free cash flow | $(27.4)M | $(10.6)M | Worse by $16.9M (Free Cash Flow table) |
| Adjusted net loss | $(3.0)M | $3.4M | Reversed to a loss (Adjusted Net Income table) |
The key miss versus the diversification narrative is profitability conversion. Despite the stronger gross profit, adjusted EBITDA declined 10% to $9.2 million, adjusted cash operating income dropped 85% to $1.2 million, and adjusted net loss widened to $3.0 million (Adjusted EBITDA; Adjusted cash operating income; Adjusted Net Income tables). Higher general and administrative, marketing, restructuring, and transaction costs absorbed the gross-profit improvement, leaving the business further from self-funded growth than the headline revenue increase suggests.
Cash generation is the more consequential weakness. Operating cash flow deteriorated to negative $16.5 million from negative $1.3 million, while adjusted free cash flow fell to negative $23.4 million from negative $4.8 million (Cash Flow statement; Free Cash Flow table). Inventory increased to $329.0 million from $301.2 million at May 31, 2026, tying up cash even as the company reported a $221.4 million pool of cash, restricted cash, and marketable securities (Balance Sheet; Key Operating Metrics).
Management preserved the annual plan, but this quarter leaves more execution concentrated in the back half. Fiscal 2027 adjusted EBITDA guidance remains $68 million to $75 million, a range already disclosed with the fiscal-year outlook rather than a new upward revision. The filing also says results are normally weighted toward the second half and especially the fourth quarter, so the unchanged guide requires a substantial improvement from the $9.2 million first-quarter run rate.
The next proof point is whether new beverage distribution can turn acquired scale into cash earnings. Tilray says Carlsberg brands will begin production and U.S. sales on January 1, 2027, giving the beverage strategy a named near-term commercial catalyst, but the current quarter shows that revenue scale alone has not yet produced better EBITDA or cash flow. 〔0〕
Bottom line: This is a mixed earnings release: Tilray is successfully enlarging the platform and improving gross margins, but the core test—converting that growth into EBITDA and cash—was not met this quarter. The unchanged annual guide keeps the strategy alive, but makes the second half much more important.
Carlsberg U.S. launch, January 1, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!